Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors

Tyrosine kinase inhibitors (TKI) are the mainstay treatment of BCR-ABL1-positive leukemia and virtually all patients with chronic myeloid leukemia in chronic phase (CP CML) respond to TKI therapy. However, there is limited information on the cellular mechanisms of response and particularly on the ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Pietarinen, Paavo O., Eide, Christopher A., Ayuda-Durán, Pilar, Potdar, Swapnil, Kuusanmäki, Heikki, Andersson, Emma I., Mpindi, John P., Pemovska, Tea, Kontro, Mika, Heckman, Caroline A., Kallioniemi, Olli, Wennerberg, Krister, Hjorth-Hansen, Henrik, Druker, Brian J., Enserink, Jorrit M., Tyner, Jeffrey W., Mustjoki, Satu, Porkka, Kimmo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410248/
https://www.ncbi.nlm.nih.gov/pubmed/28186983
http://dx.doi.org/10.18632/oncotarget.15146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410248/
https://www.ncbi.nlm.nih.gov/pubmed/28186983
http://dx.doi.org/10.18632/oncotarget.15146

Ejemplares similares